An Update on HIV-2 Infection
DOI:
https://doi.org/10.37591/rrjomv.v8i2.212Abstract
Human immunodeficiency virus type 2 (HIV–2) infection is an important cause of disease in a number of regions of the world. But the knowledge about this infection is sparse. Prevalence data on HIV-2 is heterogeneous. HIV-2 has a lower infectivity than HIV-1 which can be related to the lower RNA levels in this virus. The rate of progression to Acquired Immunodeficiency Syndrome (AIDS) in HIV-2-infected patients is highly variable making it necessary to distinguish patients who are likely to progress from those who may have a more indolent course for better monitoring of HIV-2-infected patients. Wasting syndrome and pulmonary tuberculosis occur most frequently in HIV-2-infected AIDS patients than in HIV-1 patients. Recombinant immunoblot assay appears to be more specific in detecting HIV-2 than the other immunoblot assays. The development of an FDA-approved quantitative HIV-2 RNA test is needed to improve the care of HIV-2-infected patients. CD4 cell count recovery is very slow following the initiation of treatment in many HIV-2-infected patients; therefore, it is better to start therapy for HIV-2 patients when the CD4 cell count is <500/mm. Though nucleotide reverse transcriptase inhibitors and protease inhibitors are usually active against HIV-2, there may be variation in the potency of these agents. Tenofovir plus either emtricitabine or lamivudine along with Ritonavir-boosted lopinavir or darunavir could be a reasonable treatment choice for HIV-2 infections. A high frequency of mutations including multiclass drug resistance mutations have been reported in HIV-2 patients on treatment.
Keywords: HIV-2, recombinant immunoblot assay, nucleotide reverse transcriptase inhibitors, protease inhibitors
Cite this Article
Pavani G. An Update on HIV-2 Infection. Research & Reviews: A Journal of Microbiology and Virology. 2018; 8(2): 34–42p
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
